Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Retrograde atrophy induction: a paradigm shift in prostate and pancreatic cancer prevention and therapy.

Project description

Beyond the scalpel: precision-guided tumour atrophy

Pancreatic and prostate cancers are major causes of death, yet standard surgical treatments remain highly aggressive and carry substantial disease burden. The EIC-funded PROPANTHERA project aims to replace these invasive procedures with a first-in-class, minimally invasive alternative. By introducing novel ultra-miniaturised catheters to perform targeted radiofrequency ablation of exocrine ducts, the project will induce localised retrograde atrophy to functionally eliminate tumours while preserving the organ. The project’s goal is to pave the way toward precision-guided atrophy, reducing complications, costs and recovery times. This approach may transform oncology and establish a new generation of organ-preserving interventions, especially for high-risk patients and those unfit for surgery.

Objective

Pancreatic cancer (PaC) is a leading cause of cancer-related death in the Western world and its incidence is increasing. Prostate cancer (PrC) is the 2nd most frequent cancer in men and the 5th leading cause of death globally. These tumors arise in exocrine glands with secretory ducts. Standard treatments like the Whipple procedure or radical prostatectomy are aggressive and carry significant morbidity. PROPANTHERA proposes a first-in-class, minimally invasive alternative: targeted radiofrequency ablation (RFA) of exocrine ducts to induce localized retrograde atrophy leading to functional elimination of preneoplastic lesions and tumors.
This breakthrough is enabled through the design of novel ultra-miniaturized catheters developed by world leaders in bioengineering and surgical oncology, enhanced by key expertise in state-of-the-art genome editing and genomic biology tools. The project builds on strong prior evidence in mice and uses tools ready for translation. Preclinical validation will use genetically engineered swine models mimicking human KRAS/TP53-driven and BRCA2-associated pancreatic cancer. For the first time, we will ablate lobular structures in the pancreas and the prostate in vivo, offering a precision medicine, organ-preserving approach.
PROPANTHERA pioneers a paradigm shift: replacing resection with precision-guided atrophy. This approach will reduce complications, costs, and recovery time. Its impact will be highest in high-risk patients and those unfit for surgery. PROPANTHERA will not only redefine the treatment of PaC and PrC but it will also inaugurate a new class of organ-preserving interventions for a wider range of malignancies. The new medical devices, with a clear path to CE marking, and the strong biology to guide further refinement align with EU missions to reduce cancer burden and foster innovation to impact on survival.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-EIC - HORIZON EIC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIC-2025-PATHFINDEROPEN

See all projects funded under this call

Coordinator

FUNDACION SECTOR PUBLICO ESTATAL CENTRO NACIONAL INVESTIGACIONES ONCOLOGICAS CARLOS III
Net EU contribution
€ 572 500,00
Address
C MELCHOR FERNANDEZ ALMAGRO 3
28029 Madrid
Spain
Region
Comunidad de Madrid Comunidad de Madrid Madrid
Activity type
Research Organisations
Links
Total cost
€ 572 500,00

Participants (6)